3-methylhept-6-enoic acid | 116530-70-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-methylhept-6-enoic acid
• CAS: 116530-70-2
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: PDTSTRJTHMDMHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methylhept-6-enoic acid 在 4-二甲氨基吡啶 、 草酰氯 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 S-4-methyl-2-oxooct-7-enyl 3-methylhept-6-enethioate
  参考文献：
  名称：

  muscothiazoles A和B的合成：甲基取代在基于RCM的大环合成中的关键作用。

  摘要：

  [反应：见正文]穆斯科噻唑A（2b）和B（2c）是通过两种方法制备的，这两种方法的环的组装顺序不同。比较研究表明，即使被单个甲基取代，底物5或12中的碳链（分别被RCM取代为13元和14元环的前体）也可以对提高大环化效率产生深远的影响。

  DOI：

  10.1021/ol034571i
• 作为产物：
  描述：

  (1-methyl-pent-4-enyl)-malonic acid 生成 3-methylhept-6-enoic acid
  参考文献：
  名称：

  Gol'mow, Zhurnal Obshchei Khimii, 1952, vol. 22, p. 1944,1951; engl. Ausg. S. 1993, 1998, 1999

  摘要：

  DOI：

文献信息

• [EN] MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF<br/>[FR] LACTAMES MACROCYCLIQUES ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：NOVARTIS AG

  公开号：WO2005049585A1

  公开（公告）日：2005-06-02

  The present invention relates to novel macrocyclic compounds of the formula (I) wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharma­ceutical compositions comprising them.

  本发明涉及以下式（I）的新型大环化合物，其中R1、R2、R3、U、V、W、X、Y、Z和n如规范中所定义，大环环中包含的环原子数为14、15、16或17，以自由碱形式或酸盐形式存在，以及它们的制备方法，用作药物的用途，以及包含它们的药物组合物。
• Macrocyclic lactams and pharmaceutical use thereof
  申请人：Auberson Yves

  公开号：US20070072792A1

  公开（公告）日：2007-03-29

  The present invention relates to novel macrocyclic compounds of the formula wherein R 1 , R 2 , R 3 , U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

  本发明涉及到新型大环化合物，其化学式为R1、R2、R3、U、V、W、X、Y、Z和n在规范中定义，该大环中包含的环原子数为14、15、16或17，以自由碱基形式或酸加成盐形式存在，以及它们的制备方法、它们作为药物的用途以及包含它们的药物组成物。
• Macrocyclic Lactams and Pharmaceutical Use Thereof
  申请人：AUBERSON Yves

  公开号：US20100022500A1

  公开（公告）日：2010-01-28

  The present invention relates to novel macrocyclic compounds of the formula wherein R 1 , R 2 , R 3 , U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

  本发明涉及新型大环化合物，其化学式为R1，R2，R3，U，V，W，X，Y，Z和n如规范中所定义，大环环中包括的环原子数为14，15，16或17，以游离碱形式或酸盐形式存在，涉及其制备、作为药物的使用以及包括它们的药物组成物。
• CROSSLINKED GEL FORMULATION
  申请人：ESSILOR INTERNATIONAL

  公开号：EP3985046A1

  公开（公告）日：2022-04-20

  The present invention relates to a gel medium comprising at least one non-aqueous solvent; a crosslinked polymer resulting from the reaction of : a polyfunctional polymer containing at least two carboxyl moieties capable of undergoing crosslinking reactions, said polyfunctional polymer having a molecular weight from 2,000 g/mol to 3,000,000 g/mol, preferably from 10,000 to 1,000,000 g/mol, more preferably from 25,000 g/mol to 400,000 g/mol and a crosslinking agent chosen from a polycarbodiimide or a polyaziridine.

  本发明涉及一种凝胶介质，包括至少一种非水性溶剂；由以下物质反应生成的交联聚合物：：含有至少两个能发生交联反应的羧基的多官能团聚合物，所述多官能团聚合物的分子量为 2,000 克/摩尔至 3,000,000 克/摩尔，最好为 10,000 至 1,000,000 克/摩尔，更佳为 25,000 克/摩尔至 400,000 克/摩尔；以及一种交联剂，该交联剂选自聚碳二亚胺或聚氮丙啶。
• Generation and Trapping of <i>N</i>-Acyliminium Ions Derived from Isomünchnone Cycloadducts. A Versatile Route to Functionalized Heterocycles
  作者：Michael A. Brodney、Albert Padwa

  DOI：10.1021/jo981624e

  日期：1999.1.1

  A series of 2-diazo-N-hept-6-enoylmalonamides were prepared and treated with a catalytic amount of rhodium(II) perfluorobutyrate. The resultant carbenoids underwent facile cyclization onto the neighboring amide carbonyl oxygen atom to generate isomunchnone-type intermediates. Subsequent 1,3-dipolar cycloaddition across the pendant olefin afforded intramolecular cycloadducts in high yield. The cascade sequence is simple, direct, and extremely tolerant of structural diversity. Exposure of these cycloadducts to Lewis acids resulted in oxabicyclic ring opening. N-Acyliminium ions of wide structural variety can be easily generated by this sequence of reactions. Different cyclization pathways become available depending on the nature of the substituent group attached to the amide nitrogen. When the tethered group is electrophilic in nature, proton lass from the initially formed N-acyliminium ion occurs rapidly to-give an acyl enamide which undergoes a subsequent cyclization at the electrophilic center.